Day 1 :
University of Kentucky, USA
Time : 09:45-10:25
Dr. Pavlik is a graduate of the University of Denver, and received his PhD from the University of Tennessee, Knoxville. He received a NCI Public Health Service Fellowship at the University of Illinois, Champaign Urbana, Illinois and was a Visiting Assistant Professor, Department of Physiology and Biophysics at the University of Illinois, Champaign Urbana. He is an active lecturer in the College of Medicine and organizes and mentors summer intern research including students from Denison University, Penn State University, Transylvania University, Centre College, Vassar College, the University of North Carolina, Eastern Kentucky University, Depauw University, Union College and the University of Kentucky. He is a member of the Graduate College and serves on dissertation committees for the PhD degree. Dr. Pavlik is an author on over 100 peer reviewed publications, has presented at a number of prestigious international conferences, and has been funded by the NCI, the ACS and the VA. His research focus is on ovarian cancer screening and factors that affect screening accuracy and performance. Dr. Pavlik is a member of the editorial board for: the British Journal of Medicine and Medical Research, Journal of Gynecology and Obstetrics, the Journal of Medical Oncology, the Imaging Journal of Clinical and Medical Sciences, Gynecologic and Obstetrics Research, Journal of Cancer Metastasis and Treatment, Women's Health International, Clinics in Oncology Gynecological Cancers.
Women that are positive for an ovarian abnormality in a clinical setting can have either a malignancy or a benign tumor with probability favoring the benign alternative. Discovering a malignancy as early as possible will lead to extended survival. Surgery on benign abnormalities results in unnecessary procedures introducing cost burdens. Surveillance using serial ultrasonography can be used to discover if changes in the ovarian abnormality will occur that favor either a malignant or benign interpretation. Several ovarian cancer screening trials have had experiences with changes in subclinical ovarian abnormalities in normal women that can define growth, stability or resolution and the time frame over which changes occur. The present report examines information from screening trials, and relates it to ovarian cancer ontology, presenting arguments related to the benefits of surveillance.
Intricacies of ovarian cancer screening are considered as ten considerations:
1. Deciding on the number to be screened.
2. Anticipating reductions due to death.
3. Deciding the duration and frequency of screening.
4. Deciding on the follow-up period.
5. Deciding on time to surgery.
6. Deciding on how screening cases are treated and by whom.
7. Deciding on how to treat data.
8. Deciding on how to assign disease specific death.
9. Deciding how to avoid participants with late stage disease.
10. Deciding whether the screening tool or a screening process is being tested.
The considerations presented provide explanations of effects that have an important bearing on interpreting ovarian screening outcomes and the surveillance of ovarian abnormalities in clinical practice.
University of Texas, USA
Time : 10:25-11:05
Kwong-Kwok Wong, Ph.D. is a molecular biologist and completed his PhD from the Chinese University of Hong Kong. He is currently a professor in the Department of Gynecologic Oncology and Reproductive Medicine at The University of Texas MD Anderson Cancer Center. His laboratory is interested in deciphering the molecular pathogenesis of ovarian cancer with a translational goal to identify biomarkers and therapeutic targets. One of his current projects supported by the UT MD Anderson Ovarian SPORE grant is to understand the molecular progression of low-grade serous ovarian cancer and to determine the resistance mechanisms of ovarian cancer to MEK inhibitors. He has published 78 peer-reviewed articles and 13 book chapters. He is also an inventor or co-inventor in 6 US issued patents. Dr. Wong is a regular member of the graduate faculty for The University of Texas Graduate School of Biomedical Sciences. He has trained graduate students and clinical fellows and has been named the Faculty Educator of the Month (August, 2016). He is an academic editor for PLOS One, a member of editorial board for American Journal of Clinical and Experimental Obstetrics and Gynecology, and the Editor-In-Chief for the Advances in Modern Oncology Research.
Thomas Jefferson University, USA
Time : 11:30-12:10
Cornell University, USA
Keynote: Combination epigenetic therapy for recurrent platinum-resistant-platinum refractory epithelial ovarian cancer
Time : 12:10-12:50